BPN-27473
/ AgeneBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 10, 2022
BPN-27473: a novel GABAAα5 positive allosteric modulator that improves memory performance of rats with conditions of hippocampal hyperactivity
(Neuroscience 2022)
- "Similarly, the compound significantly improved memory performance of young adult rats exposed sub-chronically to ketamine during adolescence that models the cognitive and pathophysiological phenotypes of schizophrenia. Additionally in a small pilot study, BPN-27473 was effective in reducing hippocampal neural activation induced by systemic administration of a small dose of kainic acid in normal rats to mimic hippocampal overactivity. Taken together, our data provides strong evidence supporting the use of GABAA α5 PAMs to reduce hippocampal overactivity and to treat mild cognitive impairment due to Alzheimer’s disease and cognitive impairment associated with schizophrenia."
Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Psychiatry • Schizophrenia
1 to 1
Of
1
Go to page
1